Browse > Article
http://dx.doi.org/10.4110/in.2015.15.3.142

Osteopontin Potentiates Pulmonary Inflammation and Fibrosis by Modulating IL-17/IFN-γ-secreting T-cell Ratios in Bleomycin-treated Mice  

Oh, Keunhee (Laboratory of Immunology and Cancer Biology, Department of Biomedical Sciences, Seoul National University College of Medicine)
Seo, Myung Won (Laboratory of Immunology and Cancer Biology, Department of Biomedical Sciences, Seoul National University College of Medicine)
Kim, Young Whan (Department of Internal Medicine, Seoul National University College of Medicine)
Lee, Dong-Sup (Laboratory of Immunology and Cancer Biology, Department of Biomedical Sciences, Seoul National University College of Medicine)
Publication Information
IMMUNE NETWORK / v.15, no.3, 2015 , pp. 142-149 More about this Journal
Abstract
Lung fibrosis is a life-threatening disease caused by overt or insidious inflammatory responses. However, the mechanism of tissue injury-induced inflammation and subsequent fibrogenesis remains unclear. Recently, we and other groups reported that Th17 responses play a role in amplification of the inflammatory phase in a murine model induced by bleomycin (BLM). Osteopontin (OPN) is a cytokine and extracellular-matrix-associated signaling molecule. However, whether tissue injury causes inflammation and consequent fibrosis through OPN should be determined. In this study, we observed that BLM-induced lung inflammation and subsequent fibrosis was ameliorated in OPNdeficient mice. OPN was expressed ubiquitously in the lung parenchymal and bone-marrow-derived components and OPN from both components contributed to pathogenesis following BLM intratracheal instillation. Th17 differentiation of $CD4^+$ ${\alpha}{\beta}$ T cells and IL-17-producing ${\gamma}{\delta}$ T cells was significantly reduced in OPN-deficient mice compared to WT mice. In addition, Th1 differentiation of $CD4^+$ ${\alpha}{\beta}$ T cells and the percentage of IFN-$\gamma$-producing ${\gamma}{\delta}$ T cells increased. T helper cell differentiation in vitro revealed that OPN was preferentially upregulated in $CD4^+$ T cells under Th17 differentiation conditions. OPN expressed in both parenchymal and bone marrow cell components and contributed to BLM-induced lung inflammation and fibrosis by affecting the ratio of pathogenic IL-17/protective IFN-$\gamma$ T cells.
Keywords
Osteopontin; Pulmonary fibrosis; ${\alpha}{\beta}$ T cells; IL-17; Th17 differentiation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Wynn, T. A., and T. R. Ramalingam. 2012. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18: 1028-1040.   DOI
2 Wick, G., C. Grundtman, C. Mayerl, T. F. Wimpissinger, J. Feichtinger, B. Zelger, R. Sgonc, and D. Wolfram. 2013. The immunology of fibrosis. Annu. Rev. Immunol. 31: 107-135.   DOI
3 Lo Re, S., L. Dumoutier, I. Couillin, C. Van Vyve, Y. Yakoub, F. Uwambayinema, B. Marien, S. van den Brule, J. Van Snick, C. Uyttenhove, B. Ryffel, J. C. Renauld, D. Lison, and F. Huaux. 2010. IL-17A-producing gammadelta T and Th17 lymphocytes mediate lung inflammation but not fibrosis in experimental silicosis. J. Immunol. 184: 6367-6377.   DOI
4 Wilson, M. S., S. K. Madala, T. R. Ramalingam, B. R. Gochuico, I. O. Rosas, A. W. Cheever, and T. A. Wynn. 2010. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207: 535-552.   DOI
5 Oh, K., H. B. Park, O. J. Byoun, D. M. Shin, E. M. Jeong, Y. W. Kim, Y. S. Kim, G. Melino, I. G. Kim, and D. S. Lee. 2011. Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice. J. Exp. Med. 208: 1707-1719.   DOI
6 Ishijima, M., S. R. Rittling, T. Yamashita, K. Tsuji, H. Kurosawa, A. Nifuji, D. T. Denhardt, and M. Noda. 2001. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J. Exp. Med. 193: 399-404.   DOI
7 Wang, K. X., and D. T. Denhardt. 2008. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 19: 333-345.   DOI
8 Chakraborty, G., S. Jain, and G. C. Kundu. 2008. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 68: 152-161.   DOI
9 Ahmed, M., R. Behera, G. Chakraborty, S. Jain, V. Kumar, P. Sharma, A. Bulbule, S. Kale, S. Kumar, R. Mishra, R. Raja, S. Saraswati, R. Kaur, G. Soundararajan, D. Kumar, D. Thorat, M. Sanyal, A. Ramdasi, P. Ghosh, and G. C. Kundu. 2011. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin. Ther. Targets 15: 1113-1126.   DOI
10 Yamamoto, N., F. Sakai, S. Kon, J. Morimoto, C. Kimura, H. Yamazaki, I. Okazaki, N. Seki, T. Fujii, and T. Uede. 2003. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J. Clin. Invest. 112: 181-188.   DOI
11 Weber, G. F., S. Ashkar, M. J. Glimcher, and H. Cantor. 1996. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271: 509-512.   DOI
12 Kanayama, M., D. Kurotaki, J. Morimoto, T. Asano, Y. Matsui, Y. Nakayama, Y. Saito, K. Ito, C. Kimura, N. Iwasaki, K. Suzuki, T. Harada, H. M. Li, J. Uehara, T. Miyazaki, A. Minami, S. Kon, and T. Uede. 2009. Alpha9 integrin and its ligands constitute critical joint microenvironments for development of autoimmune arthritis. J. Immunol. 182: 8015-8025.   DOI
13 Diao, H., K. Iwabuchi, L. Li, K. Onoe, L. Van Kaer, S. Kon, Y. Saito, J. Morimoto, D. T. Denhardt, S. Rittling, and T. Uede. 2008. Osteopontin regulates development and function of invariant natural killer T cells. Proc. Natl. Acad. Sci. U. S. A. 105: 15884-15889.   DOI
14 Morimoto, J., S Kon, Y. Matsui, and T. Uede. 2010. Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr. Drug Targets 11: 494-505.   DOI
15 Diao, H., S. Kon, K. Iwabuchi, C. Kimura, J. Morimoto, D. Ito, T. Segawa, M. Maeda, J. Hamuro, T. Nakayama, M. Taniguchi, H. Yagita, L. K. Van Kaer, Onoe, D. Denhardt, S. Rittling, and T. Uede. 2004. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21: 539-550.   DOI
16 Chung, J. W., M S. Kim, Z. H. Piao, M. Jeong, S. R. Yoon, N. Shin, S. Y. Kim, E. S. Hwang, Y. Yang, Y. H. Lee, Y. S. Kim, and I. Choi. 2008. Osteopontin promotes the development of natural killer cells from hematopoietic stem cells. Stem Cells 26: 2114-2123.   DOI
17 Weber, C. E., N. Y. Li, P. Y. Wai, and P. C. Kuo. 2012. Epithelial-mesenchymal transition, TGF-$\beta$, and osteopontin in wound healing and tissue remodeling after injury. J. Burn. Care Res. 33: 311-318.   DOI
18 Liaw. L., D. E. Birk, C. B. Ballas, J. S. Whitsitt, J. M. Davidson, and B. L. Hogan. 1998. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J. Clin. Invest. 101: 1468-1478.   DOI
19 Konno, S., M. Kurokawa, T. Uede, M. Nishimura, and S. K. Huang. 2011. Role of osteopontin, a multifunctional protein, in allergy and asthma. Clin. Exp. Allergy 41: 1360-1366.   DOI
20 Pardo, A., K. Gibson, J. Cisneros, T. J. Richards, Y. Yang, C. Becerril, S. Yousem, I. Herrera, V. Ruiz, M. Selman, and N. Kaminski. 2005. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2: e251.   DOI
21 Cantor, H., and M. L. Shinohara. 2009. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat. Rev. Immunol. 9: 137-141.   DOI
22 Kelly, M. M., R. Leigh, S. E. Gilpin, E. Cheng, G. E. Martin, K. Radford, G. Cox, and J. Gauldie. 2006. Cell-specific gene expression in patients with usual interstitial pneumonia. Am. J. Respir. Crit. Care Med. 174: 557-565.   DOI
23 Takahashi, F., K. Takahashi, T. Okazaki, K. Maeda, H. Ienaga, M. Maeda, S. Kon, T. Uede, and Y. Fukuchi. 2001. Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 24: 264-271.   DOI
24 Shinohara, M. L., L. Lu, J. Bu, M. B. Werneck, K. S. Kobayashi, L. H. Glimcher, and H. Cantor. 2006. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. Nat. Immunol. 7: 498-506.   DOI
25 Baroni G. S., L. D'Ambrosio, P. Curto, A. Casini, R. Mancini, A. M. Jezequel, and A. Benedetti. 1996. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23: 1189-1199.   DOI
26 Giri, S. N., D. M. Hyde, and B. J. Marafino Jr. 1986. Ameliorating effect of murine interferon gamma on bleomycin-induced lung collagen fibrosis in mice. Biochem. Med. Metab. Biol. 36: 194-197.   DOI
27 Oldroyd, S. D., G. L. Thomas, G. Gabbiani, and A. M. EI Nahas. 1996. Interferon-gamma inhibits experimental renal fibrosis. Kidney Int. 56: 2116-2127.
28 Ashkar, S., G. F. Weber, V. Panoutsakopoulou, M. E. Sanchirico, M. Jansson, S. Zawaideh, S. R. Rittling, D. T. Denhardt, M. J. Glimcher, and H. Cantor. 2000. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287: 860-864.   DOI
29 Shinohara, M. L., J. H. Kim, V. A. Garcia, and H. Cantor. 2008. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 29: 68-78.   DOI
30 Murugaiyan, G., A. Mittal, and H. L. Weiner. 2010. Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc. Natl. Acad. Sci. U. S. A. 107: 11495-11500.   DOI
31 Wynn, T. A., 2004. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4: 583-594.   DOI
32 Braun, R. K., C. Ferrick, P. Neubauer, M. Sjoding, A. Sterner-Kock, M. Kock, L. Putney, D. A. Ferrick, D. M. Hyde, and R. B. Love. 2008. IL-17 producing gammadelta T cells are required for a controlled inflammatory response after bleomycin-induced lung injury. Inflammation 31: 167-179.   DOI
33 Simonian, P. L., C. L. Roark, F. Diaz del Valle, B. E. Palmer, I. S. Douglas, K. Ikuta, W. K. Born, R. L. O'Brien, and A. P. Fontenot. 2006. Regulatory role of gammadelta T cells in the recruitment of $CD4^+$ and $CD8^+$ T cells to lung and subsequent pulmonary fibrosis. J. Immunol. 177: 4436-4443.   DOI
34 Wynn, T. A. 2011. Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208: 1339-1350.   DOI
35 Brown, L. F., B. Berse, L. Van de Water, A. Papadopoulos-Sergiou, C. A. Perruzzi, E. J. Manseau, H. F. Dvorak, and D. R. Senger. 1992. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol. Biol. Cell 3: 1169-1180.   DOI
36 Berman, J. S., D. Serlin, X. Li, G. Whitley, J. Hayes, D.C. Rishikof, D. A. Ricupero, L. Liaw, M. Goetschkes, and A. W. O'Regan. 2004. Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 286: L1311-1318.   DOI
37 Simonian, P. L., F. Wehrmann, C. L. Roark, W. K. Born, R. L. O'Brien, and A. P. Fontenot. 2010. ${\gamma}{\delta}T$ cells protect against lung fibrosis via IL-22. J. Exp. Med. 207: 2239-2253.   DOI
38 Sonnenberg, G. F., M. G. Nair, T. J. Kirn, C. Zaph, L. A. Fouser, and D. Artis. 2010. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J. Exp. Med. 207: 1293-12305.   DOI
39 Katagiri, Y. U., J. Sleeman, H. Fujii, P. Herrlich, H. Hotta, K. Tanaka, S. Chikuma, H. Yagita, K. Okumura, M. Murakami, I. Saiki, A. F. Chambers, and T. Uede. 1999. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 59: 219-226.
40 Ashizawa, N., K. Graf, Y. S. Do, T. Nunohiro, C. M. Giachelli, W. P. Meehan, T. L. Tuan, W. A. Hsueh. 1996. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J. Clin. Invest. 98: 2218-2227.   DOI